We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

44 hedge funds and large institutions have $63.7M invested in Adamas Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

16% more funds holding

Funds holding: 38 → 44 (+6)

12% more capital invested

Capital invested by funds: $57M → $63.7M (+$6.7M)

0% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 14

Holders
44
Holders Change
+6
Holders Change %
+15.79%
% of All Funds
1.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
14
Reduced
14
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.85M
2
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
+$1.15M
3
GPCM
Granite Point Capital Management
Massachusetts
+$1.06M
4
State Street
State Street
Massachusetts
+$391K
5
Citadel Advisors
Citadel Advisors
Florida
+$391K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$586K
2
Jane Street
Jane Street
New York
-$545K
3
ACM
Ativo Capital Management
Illinois
-$514K
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$486K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$351K
Name Holding Trade Value Shares
Change 		Change in
Stake
B
26
Barings
North Carolina
$190K +$175K +10,200 New
TCIM
27
TIAA CREF Investment Management
New York
$178K +$21.3K +1,240 +15%
BIM
28
BlackRock Investment Management
Delaware
$158K +$12.6K +731 +9%
Acadian Asset Management
29
Acadian Asset Management
Massachusetts
$134K +$123K +7,177 New
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$99K +$533 +31 +0.6%
TA
31
Teachers Advisors
New York
$77K – – –
Deutsche Bank
32
Deutsche Bank
Germany
$73K -$112K -6,486 -62%
SO
33
STRS Ohio
Ohio
$48K +$44.7K +2,596 New
NFA
34
Nationwide Fund Advisors
Ohio
$41K +$2.15K +125 +6%
AIG
35
American International Group
New York
$35.6K – – –
U
36
UBS
Switzerland
$27K +$14.3K +832 +131%
Morgan Stanley
37
Morgan Stanley
New York
$7K -$174K -10,110 -96%
AllianceBernstein
38
AllianceBernstein
Tennessee
$7K -$6.88K -400 -50%
Wells Fargo
39
Wells Fargo
California
$3K -$1.26K -73 -35%
Citigroup
40
Citigroup
New York
$2K +$688 +40 +63%
DA
41
Denali Advisors
California
$2K +$1.72K +100 New
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$1.71K +$1.58K +92 New
Barclays
43
Barclays
United Kingdom
$1K -$585 -34 -53%
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$14 +$12.6K +732 New
Jane Street
45
Jane Street
New York
– -$545K -29,826 Closed
ACM
46
Ativo Capital Management
Illinois
– -$514K -28,125 Closed
TRCT
47
Tower Research Capital (TRC)
New York
– -$54K -2,969 Closed
VFA
48
Virtus Fund Advisers
Connecticut
– -$5K -249 Closed
1
2

ADMS Hedge Fund Activity: Q3 2014 in Review

44 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2014, worth a combined $63.7M — up 12% from $57M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ADMS positions and 4 closed out — a net gain of 6 holders — while 14 added to existing stakes and 14 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $3.85M. The largest seller was JP Morgan Chase, cutting an estimated $586K.

  • 44 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2014, up from 38 in Q2 2014.
  • Funds reported $63.7M of Adamas Pharmaceuticals stock for Q3 2014, up 12% quarter-over-quarter.
  • 10 funds opened new Adamas Pharmaceuticals positions in Q3 2014 and 4 closed out, a net change of +6 holders.
  • The largest Adamas Pharmaceuticals buyer in Q3 2014 was Fidelity Investments, an estimated $3.85M added.
  • The largest Adamas Pharmaceuticals seller in Q3 2014 was JP Morgan Chase, an estimated $586K sold.

Based on aggregated 13F filings for Q3 2014.